Dennis Wooley
Nurse Practitioner · Columbia, KYNPI 1184628075
Payments from drug & device makers
Across 104 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$280
- Lilly USA, LLC$201
- Alkermes, Inc.$197
- Axsome Therapeutics, Inc.$173
- Amgen$121
- GSK$96
- plus $657 from 19 others
What the payments were for
- Food & beverage$1,70999%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 16 | $280 |
| Lilly USA, LLC | 13 | $201 |
| Alkermes, Inc. | 14 | $197 |
| Axsome Therapeutics, Inc. | 9 | $173 |
| Amgen | 7 | $121 |
| GSK | 6 | $96 |
| AstraZeneca | 5 | $92 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $79 |
| Pfizer | 5 | $68 |
| Amarin Pharma, Inc. | 4 | $59 |
| Boehringer Ingelheim | 3 | $48 |
| Vanda Pharmaceuticals Inc. | 2 | $44 |
| Johnson & Johnson | 3 | $40 |
| Ultragenyx Pharmaceutical Inc. | 1 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Optinose US, Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Novartis | 1 | $16 |
| Bayer | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Merck | 1 | $13 |
How this compares
$1,725 in reported general payments places this provider in the 75th percentile of 1,918 nurse practitioner providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 90 | $98,845 |
| EliquisApixaban | 94 | $81,406 |
| OzempicSemaglutide | 54 | $50,076 |
| MounjaroTirzepatide | 27 | $36,174 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $28,340 |
| JanuviaSitagliptin Phosphate | 26 | $27,570 |
| XareltoRivaroxaban | 35 | $27,412 |
| Breo ElliptaFluticasone/Vilanterol | 65 | $25,632 |
| TrulicityDulaglutide | 28 | $25,479 |
| Repatha SyringeEvolocumab | 18 | $15,567 |
| LinzessLinaclotide | 28 | $15,475 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $14,042 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $9,452 |
| Spiriva RespimatTiotropium Bromide | 18 | $9,400 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $8,559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat | $48 | $117,698127 claims |
| PfizerEliquis | $68 | $81,40694 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $96 | $75,484164 claims |
| Lilly USA, LLCMounjaro, Trulicity | $201 | $61,65355 claims |
| MerckJanuvia | $13 | $27,57026 claims |
| Johnson & JohnsonXarelto | $40 | $27,41235 claims |
| AbbVieLinzess | $280 | $15,47528 claims |
| AstraZenecaBrilinta, Symbicort | $92 | $8,59323 claims |
| Sanofi-aventis U.S. LLCLantus | $13 | $3,19117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,918 nurse practitioner providers in Kentucky.
Other nurse practitioner in Columbia
- Rachael BradfordLexington$447K
- Tara MuddLouisville$243K
- Lee HaasLouisville$95K
- Ashley KnableLouisville$86K
- Christina BenningerLouisville$81K
- Courtney BowlingCampbellsville$47K
- Rebecca BraunerLouisville$40K
- Scott SeitzWinchester$34K
- Kristen KreinestEdgewood$34K
- Lillian ArgentEdgewood$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.